Corporations Act 2001 Section 671B

Notice of change of interests of substantial holder

To Company Name/Scheme Actinogen Medical Limited

ACN/ARSN 086 778 476

1. Details of substantial holder (1)

Name BVF Partners L.P. on its own behalf and on behalf of BVF Inc. and Mark N. Lampert

ACN/ARSN (if applicable)

There was a change in the interests of the

substantial holder on

23/12/2024, 27/12/2024, 31/12/2024, 2/1/2025, 3/1/2025, 6/1/2025, 7/1/2025, 8/1/2025, 9/1/2025, 10/1/2025, 13/1/2025, 14/1/2025, 15/1/2025, 16/1/2025, 17/1/2025, 20/1/2025, 21/1/2025, 22/1/2025, 23/1/2025, 24/1/2025, 27/1/2025, 28/1/2025, 30/1/2025, 31/1/2025, 3/2/2025, 14/4/2025, 15/4/2025, 16/4/2025, and 17/4/2025

The previous notice was given to the company

18/12/2024 18/12/2024

The previous notice was dated

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4)	Previous notice		Present notice		
Class of securities (4)	Person's votes	Voting power (5)	Person's votes	Voting power (5)	
Fully Paid Ordinary Shares	228,334,680	7.29%	198,244,103	6.24%	

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
23/12/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 3,242.41	131,535 fully paid ordinary shares	131,535
23/12/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	paid ordinary shares	\$ 4,986.23	202,276 fully paid ordinary shares	202,276
23/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 5,669.15	229,980 fully paid ordinary shares	229,980
23/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 16,428.25	666,444 fully paid ordinary shares	666,444

23/12/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 217.25	8,890 fully paid ordinary shares	8,890
23/12/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 518.36	21,644 fully paid ordinary shares	21,644
23/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 6,986.58	291,726 fully paid ordinary shares	291,726
23/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 7,514.73	313,779 fully paid ordinary shares	313,779
27/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 2,483.01	99,123 fully paid ordinary shares	99,123
27/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 3,099.61	123,738 fully paid ordinary shares	123,738
27/12/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 53.61	2,280 fully paid ordinary shares	2,280
27/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 6,821.96	284,818 fully paid ordinary shares	284,818
27/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 8,602.46	359,154 fully paid ordinary shares	359,154
31/12/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 21.30	0,912 fully paid ordinary shares	912
31/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 7,307.41	298,859 fully paid ordinary shares	298,859
31/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 7,518.44	307,490 fully paid ordinary shares	307,490
2/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 447.51	17,419 fully paid ordinary shares	17,419
2/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 2,157.72	83,800 fully paid ordinary shares	83,800
2/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 12,510.43	485,872 fully paid ordinary shares	485,872
2/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 16,713.52	649,109 fully paid ordinary shares	649,109
3/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 1,261.16	49,791 fully paid ordinary shares	49,791
3/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and	On Market sale of fully paid ordinary shares	\$ 3,536.04	139,493 fully paid ordinary shares	139,493

3/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 21,088.73	831,929 fully paid ordinary shares	831,929
3/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 27,367.00	1,079,600 fully paid ordinary shares	1,079,600
6/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 232.91	9,298 fully paid ordinary shares	9,298
6/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 876.84	35,004 fully paid ordinary shares	35,004
6/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 5,484.35	218,938 fully paid ordinary shares	218,938
6/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 6,440.27	257,099 fully paid ordinary shares	257,099
7/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 891.80	34,770 fully paid ordinary shares	34,770
7/1/2025		On Market sale of fully paid ordinary shares	\$ 1,738.57	67,784 fully paid ordinary shares	67,784
7/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 11,163.48	435,247 fully paid ordinary shares	435,247
7/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 11,592.73	451,983 fully paid ordinary shares	451,983
8/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 59.69	2,364 fully paid ordinary shares	2,364
8/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 5,286.77	209,382 fully paid ordinary shares	209,382
8/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 7,732.58	306,248 fully paid ordinary shares	306,248
9/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 563.46	22,444 fully paid ordinary shares	22,444
9/1/2025		On Market sale of fully paid ordinary shares	\$ 2,067.95	82,226 fully paid ordinary shares	82,226
9/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 3,627.25	144,227 fully paid ordinary shares	144,227
9/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 4,017.35	159,738 fully paid ordinary shares	159,738

ı

10/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 616.47	25,525 fully paid ordinary shares	25,525
10/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 1,946.98	80,615 fully paid ordinary shares	80,615
10/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 14,169.40	586,686 fully paid ordinary shares	586,686
10/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 17,686.51	732,312 fully paid ordinary shares	732,312
13/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 592.56	23,750 fully paid ordinary shares	23,750
13/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 1,812.17	72,632 fully paid ordinary shares	72,632
14/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 511.22	20,167 fully paid ordinary shares	20,167
14/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 11,871.31	468,311 fully paid ordinary shares	468,311
14/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 14,706.34	580,150 fully paid ordinary shares	580,150
15/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 2,879.13	115,396 fully paid ordinary shares	115,396
15/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 5,372.41	215,327 fully paid ordinary shares	215,327
16/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 396.78	15,410 fully paid ordinary shares	15,410
16/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 1,018.22	39,545 fully paid ordinary shares	39,545
16/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 11,792.66	457,996 fully paid ordinary shares	457,996
16/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 15,559.35	604,284 fully paid ordinary shares	604,284
17/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 143.33	5,632 fully paid ordinary shares	5,632
17/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 287.01	11,278 fully paid ordinary shares	11,278
/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 5,599.39	220,024 fully paid ordinary shares	220,024

17/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 6,291.58	247,223 fully paid ordinary shares	247,223
20/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 161.24	6,262 fully paid ordinary shares	6,262
20/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 364.57	14,159 fully paid ordinary shares	14,159
20/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 2,097.75	81,471 fully paid ordinary shares	81,471
20/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 2,123.52	82,472 fully paid ordinary shares	82,472
21/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	paid ordinary shares	\$	2,149 fully paid ordinary shares	2,149
21/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 523.39	20,406 fully paid ordinary shares	20,406
21/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 3,184.30	124,151 fully paid ordinary shares	124,151
21/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 5,670.65	221,090 fully paid ordinary shares	221,090
22/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	paid ordinary shares	\$ 167.49	6,713 fully paid ordinary shares	6,713
22/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 452.92	18,153 fully paid ordinary shares	18,153
22/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 3,616.48	144,949 fully paid ordinary shares	144,949
22/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 4,474.76	179,349 fully paid ordinary shares	179,349
23/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 146.61	5,876 fully paid ordinary shares	5,876
23/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 429.99	17,234 fully paid ordinary shares	17,234
23/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 3,579.18	143,454 fully paid ordinary shares	143,454
23/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 3,924.66	157,301 fully paid ordinary shares	157,301

24/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$	414.30	16,216 fully paid ordinary shares	16,216
24/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$	479.40	18,764 fully paid ordinary shares	18,764
24/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$	2,166.64	84,804 fully paid ordinary shares	84,804
24/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$	2,941.74	115,142 fully paid ordinary shares	115,142
27/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$	262.16	10,383 fully paid ordinary shares	10,383
27/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$	934.58	37,014 fully paid ordinary shares	37,014
27/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$	6,598.58	261,336 fully paid ordinary shares	261,336
27/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$	8,057.56	319,119 fully paid ordinary shares	319,119
28/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$	622.36	24,265 fully paid ordinary shares	24,265
28/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$	1,494.52	58,269 fully paid ordinary shares	58,269
28/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$	10,341.90	403,215 fully paid ordinary shares	403,215
28/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$	12,582.69	490,580 fully paid ordinary shares	490,580
30/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$	296.90	11,184 fully paid ordinary shares	11,184
30/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$	4,589.81	172,895 fully paid ordinary shares	172,895
30/1/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$	7,448.85	280,593 fully paid ordinary shares	280,593
31/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$	179.16	6,649 fully paid ordinary shares	6,649
31/1/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value	On Market sale of fully paid ordinary shares	\$		24,121 fully paid ordinary shares	24,121
	Trading Fund OS LP		<u> </u>			

ı

31/1/2025	BVF II GP LLC and Biotechnology Value Fund II, L.P	paid ordinary shares [*]	\$	160,133 fully paid ordinary shares	160,133
31/1/2025	Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 5,621.56	208,623 fully paid ordinary shares	208,623
3/2/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$ 81.43	3,056 fully paid ordinary shares	3,056
3/2/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$ 327.17	12,278 fully paid ordinary shares	12,278
3/2/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	paid ordinary shares ´	\$ 2,832.24	106,289 fully paid ordinary shares	106,289
3/2/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	paid ordinary shares	\$ 3,212.49	120,559 fully paid ordinary shares	120,559
14/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$ 101,255.18	3,498,555 fully paid ordinary shares	3,498,555
15/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$ 13,658.24	478,518 fully paid ordinary shares	478,518
15/4/2025	BVF Partners L.P., BVF	On Market sale of fully paid ordinary shares	\$ 35,251.33	1,235,034 fully paid ordinary shares	1,235,034
16/4/2025	BVF Partners L.P., BVF	On Market sale of fully paid ordinary shares	\$ 4,898.17	167,508 fully paid ordinary shares	167,508
16/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	paid ordinary shares ُ	\$ 9,467.28	323,763 fully paid ordinary shares	323,763
17/4/2025	BVF Partners L.P., BVF	On Market sale of fully paid ordinary shares	\$ 74,858.05	2,809,291 fully paid ordinary shares	2,809,291
17/4/2025	BVF Partners L.P., BVF	On Market sale of fully paid ordinary shares	\$ 100,419.20	3,768,556 fully paid ordinary shares	3,768,556

4. Present relevant interests

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
BVF Partners, L.P.	HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd	Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF	Relevant interest arises under section 608(1)(b) of the Corporations Act 2001 (Cth) (Corporations Act) by virtue of BVF Partners, L.P. (i) acting as general partner of, and/or (ii) acting as investment manager of, respectively, the registered holders of the securities, whereby it holds the authority to cast votes in respect of the securities.	198,244,103 fully paid ordinary shares	198,244,103
BVF Inc. and Mark N. Lampert	HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd		Relevant interest arises under section 608(3)(b) of the Corporations Act as each of BVF Inc. and Mark N. Lampert controls BVF Partners, L.P.	198,244,103 fully paid ordinary shares	198,244,103
BVF Partners OS Ltd.	HSBC Custody Nominees (Australia) Limited	BVF Partners OS Ltd.	Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF Partners OS, Ltd. acting as general partner of Biotechnology Value Trading Fund OS, L.P., a registered holder of securities, whereby it holds the authority to cast votes in respect to the securities.	10,938,610 fully paid ordinary shares	10,938,610
Biotechnology Value Trading Fund OS, L.P.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Trading Fund OS, L.P.	Relevant interest arises under section 608(1)(a) of the Corporations Act as holder of the securities	10,938,610 fully paid ordinary shares	10,938,610
BVF I GP LLC	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Fund, L.P.	Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF I GP LLC. acting as general partner of Biotechnology Value Fund, L.P., whereby it holds the authority to cast votes in respect of the securities.	103,583,425 fully paid ordinary shares	103,583,425
Biotechnology Value Fund, L.P.	HSBC Custody Nominees (Australia) Limited	,	Relevant interest arises under sections 608(1)(b) and 608(1)(c) of the Corporations Act as beneficial holder of the securities	103,583,425 fully paid ordinary shares	103,583,425
BVF II GP LLC	HSBC Custody Nominees (Australia) Limited		Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF II GP LLC. acting as general partner of Biotechnology Value Fund II, L.P., whereby it holds the authority to cast votes in respect of the securities.	79,680,301 fully paid ordinary shares	79,680,301
Biotechnology Value Fund II, L.P.	HSBC Custody Nominees (Australia) Limited		Relevant interest arises under sections 608(1)(b) and 608(1)(c) of the Corporations Act as beneficial holder of the securities	79,680,301 fully paid ordinary shares	79,680,301
MSI BVF SPV, LLC	BNP Paribas Nominees Pty Ltd			4,041,767 fully paid ordinary shares	4,041,767

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

	Name applicable	and e)	ACN/ARSN	(if	Nature of association
ĺ	Not applicable				Not applicable

6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
BVF Partners L.P. BVF I GP LLC BVF II GP LLC Biotechnology Value Fund, L.P. Biotechnology Value Fund II, L.P. BVF Inc.	44 Montgomery Street, 40 th Floor San Francisco, California 94104 United States of America
BVF Partners OS, Ltd Biotechnology Value Trading Fund OS,	PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands
MSI BVF SPV, LLC	c/o Magnitude Capital, L.L.C. 200 Park Avenue, 56 th Floor New York, NY 10166
Mark N. Lamport	c/o BVF Inc 44 Montgomery Street, 40 th Floor San Francisco, California 94104 United States of America

Signature

print name Mark Lampert on behalf of himself, BVF Partners L.P., and BVF Inc. capacity Director and Officer of the Substantial Holders